178 results about "Tumor Biomarkers" patented technology

The present application discloses an epigenetic marker for colon cancer.

Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.

Quantification of a target analyte is performed using a single sample to which amounts of the target analyte are added. Calibration is performed as part of quantification on the same sample. The target analyte is detectable and quantifiable using label free reagents and requiring no sample preparation. Target analytes include biomarkers such as cancer biomarkers, pathogenic Escherichia coli, single stranded DNA, and staphylococcal enterotoxin. The quantification process includes determining a sensor response of a sensor exposed to the sample and configured to detect the target analyte. Sensor responses are determined after sequential additions of the target analyte to the sample. The amount of target analyte detected by the sensor when first exposed to the sample is determined in accordance with the multiple sensor responses.

The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer.

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Applications in nanomedicine, such as diagnostics and targeted therapeutics, rely on the detection and targeting of membrane biomarkers. The present invention, in one embodiment, utilizes quantitative profiling, spatial mapping, and multiplexing of cancer biomarkers using functionalized quantum dots. This approach provides highly selective targeting molecular markers for pancreatic cancer with extremely low levels of non-specific binding and provides quantitative spatial information of biomarker distribution on a single cell, which is important since tumors cell populations are inherently heterogeneous. The quantitative measurements (number of molecules per square micron) is validated using flow cytometry and demonstrated using multiplexed quantitative profiling using color-coded quantum dots.

The present invention relates to, for example, (1) a novel method for identification of clinically useful serum and/or tumor biomarkers and expression signatures that can be used for detection, prognostication and guidance for the treatment of patients with hepatocellular carcinoma (HCC); and (2) discovery of an expression signature that can be used to monitor and/or study the efficacy of a chemotherapeutic regimen, such as, for example, sorafenib (solely or in combination with other agents). The present invention also provides a method for predicting clinical outcomes, such as, for example, overall survival (OS), time to progression (TTP) and/or likelihood of benefitting from a chemotherapeutic treatment (i.e., sorafenib) in HCC patients based on the analysis of such biomarkers.

A method of evaluating a probability a subject has a cancer, diagnosing a cancer and/or monitoring cancer progression comprising: a. measuring an amount of a biomarker selected from the group consisting of CUZD1 and/or LAMC2 and/or the group CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, KLK3, NPY, PSCA, RLN1, SLC45A3, DSP, GP73, DSG2, CEACAM7, CLCA1, GPA33, LEFTY1, ZG16, IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC, TMEM100, NPY, PSCA, RLN1 and/or SLC45A3 in a test sample from a subject with cancer; wherein the cancer is pancreas cancer if CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, LAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, DSP, GP73 and/or DSG2 is selected; the cancer is colon cancer if CEACAM7, CLCA1, GPA33, LEFTY1 and/or ZG16 is selected, the cancer is lung cancer if IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC and/or TMEM100 is selected; or the cancer is prostate cancer if NPY, PSCA, RLN1 and/or SLC45A3 is selected; b. comparing the measured amount to a control and detecting an increase in the amount of the biomarker compared to control; and c. identifying the subject as having or having an increased probability of having the cancer when an increase in the biomarker compared to control is detected.

Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.

The present invention provide a system and a method for detection of cancer, by producing a serum proteome standard by an image mining technique, and provide cancer-specific biomarkers. Disclosed is a method of analyzing cancer, comprising the steps of transforming serum proteomes from normal individuals and individuals having cancer into two-dimensional images, and constructing a database consisting of the proteome standard by an image mining technique; inputting a serum proteome from a subject of interest, transforming the serum proteome into a image and comparing the structure of the serum proteome pattern of the subject with the proteome standard and determining whether the serum proteome of the subject is normal or abnormal. The system and method for cancer analysis facilitates detection of cancer by constructing a database from a plurality of serum proteome using an image technique and comparing serum proteome of a subject with a proteome standard.

The invention provides a method for the assessment of biological markers in a sample of tissue, cells or fluid for the detection a malignant or pre-malignant condition. Aspects of the present invention are particularly useful in screening samples such as cervical smears from women to detect such markers. Identification of a malignant or pre-malignant condition may be followed by appropriate treatment.

The invention discloses an SERS sensor for integrated detection of tumor protein and nucleic acid markers and a preparation method thereof. The SERS sensor comprises a silver nanorod array substrate and an SERS probe, wherein the surface of the silver nanorod array substrate is modified with a tetrahedral DNA structure; the tetrahedral DNA structure is formed by self-assembling six DNA single chains, and three DNA single chains are arranged on three edges of the tetrahedral DNA structure, are respectively connected with three capture chains and are used for respectively and specifically binding nucleic acid and a protein marker. The detection limits of the SERS sensor for detecting nucleic acid and protein respectively reach the Amol/L magnitude and the fg/mL magnitude; the integrated detection of various nucleic acid and protein biomarkers in complex environments such as serum can be realized. The sensor disclosed by the invention is simple to prepare, high in detection sensitivity and good in reliability, can realize high-sensitivity detection of biomarkers with extremely low abundance in the early stage of lung cancer, and has good universality for various tumor biomarkers.

The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD⁴⁺, CD⁸⁺ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.